DeNovaMed ^Private

DeNovaMed is an early-stage pharmaceutical company based in Halifax, Nova Scotia, Canada. They specialize in developing novel antibiotics to combat the toughest bacterial infections, particularly those affecting diabetic patients. Their team has deep expertise in drug discovery, microbiology, and bacterial lipid metabolism. DeNovaMed's lead compound, DNM0547, is a first-in-class antibiotic with high skin permeability, making it a promising candidate for topical treatment. They are dedicated to addressing serious health issues, such as diabetic foot ulcers, with their innovative solutions.